AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02848456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
Study NCT02848456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Max Voluntary Isometric Contraction
Description: A 10 second plantar flexion maximal voluntary isometric contraction
Study NCT02848456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SM+MVIC
Description: The spinal manipulation immediately preceding the maximal voluntary isometric contraction
Study NCT02544347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: gingival crevicular fluid
Description: gingival crevicular fluid was collected
Study NCT02544347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed
Study NCT01970644 — intervention group
Intervention type: RADIATION
Intervention: Gamma knife radiosurgery
Description: Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
Study NCT02276742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
Study NCT02276742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
Study NCT00529243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
Study NCT02970591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional dietary advice and low FODMAP content
Description: Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
Study NCT02970591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
Study NCT02970591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Medical treatment
Description: Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
Study NCT04202666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: convex skin barrier
Description: Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
Study NCT04896190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position
Description: Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
Study NCT04771026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
Study NCT03429322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Care and Resource Facilitation
Description: The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
Study NCT03429322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive and provide usual and customary care in their communities.
Study NCT01216397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin (standard batch)
Description: Fixed dose combination tablet
Study NCT01216397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin (side batch)
Description: Fixed dose combination tablet
Study NCT02915887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Taping
Description: Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
Study NCT04387929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of anti-COVID-19 antibody level
Description: Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
Study NCT02949024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVT Aflibercept
Description: IVT aflibercept \[2 mg (50 µL)\]
Study NCT02949024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC CLS-TA
Description: \[4 mg (100 µL)\]
Study NCT03108521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg.QD for 3 months
Study NCT01706653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - low
Study NCT01706653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - medium
Study NCT01706653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - high
Study NCT01706653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Very low polyphenol fruit based drink (control)
Study NCT02668341 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional survey study
Study NCT04210661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prediction software with spell checker
Description: test with prediction software with spell checker
Study NCT04210661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prediction software with spell checker
Description: test with prediction software with spell checker
Study NCT03469167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEGP003
Description: Application of CEGP003 to peptic ulcer bleeding
Study NCT03469167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Tx
Description: Injection of epinephrine to peptic ulcer bleeding
Study NCT04436445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: dry cupping
Description: represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
Study NCT04436445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life style modification
Description: Life style modification
Study NCT01043744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Description: Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)
Study NCT02465476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: treatment pathway organized by telemedicine
Study NCT01539447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: • Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
Study NCT01539447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: • Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
Study NCT02212665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intense interval training
Study NCT02212665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased daily activity detected by the pedometer
Study NCT02212665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased daily activity detected by the pedometer+HIIT
Study NCT02212665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased daily activity detected by the pedometer+group intervention
Study NCT02505373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Description: The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years.
Study NCT02505373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
Study NCT02854995 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: circumcision
Description: (i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
Study NCT02854995 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: preputioplasty with intralesional injection of triamcinolone:
Description: (ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
Study NCT03725072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
Study NCT01188941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System Navigator
Description: Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
Study NCT02664480 — intervention group
Intervention type: OTHER
Intervention: Salivary alpha-Amylases
Description: Investigators will collect Salivary alpha-Amylases before and after ovulation
Study NCT02628444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT02628444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous
Study NCT00784368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ Oral Solution
Description: ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
Study NCT00784368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ-IV
Description: 200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
Study NCT06375525 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Janssen's icon Application (App)
Study NCT01518790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 3350
Description: PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
Study NCT03567889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daromun
Description: Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
Study NCT03567889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
Study NCT03567889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
Study NCT03567889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Description: Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
Study NCT03128359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03567889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
Study NCT00712387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LapSim simulator
Description: Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
Study NCT04579666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (APL-2)
Description: Complement (C3) Inhibitor
Study NCT04579666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of equal volume to active arm
Study NCT01082627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: 250ug/h,Continuous I.V. infusion,maximal 14 days
Study NCT01082627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: common daily practice
Description: common daily practice
Study NCT02969642 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Argus Migraine Treatment device
Description: treatment of Migraines targeting Sphenopalatine ganglion
Study NCT02969642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argus Migraine Treatment device
Description: treatment of Migraines targeting Sphenopalatine ganglion
Study NCT00540696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses.
Study NCT03951610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test lens
Description: contact lens
Study NCT03951610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: contact lens
Study NCT03951610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control lens
Description: contact lens
Study NCT03951610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control lens
Description: contact lens
Study NCT04146337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal microbiota in frozen capsules
Study NCT01126190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neugranin
Description: Neugranin will be administered per dose and schedule specified in the arm description.
Study NCT01126190 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered per dose and schedule specified in the arm description.
Study NCT01126190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
Study NCT01126190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
Study NCT02250976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livasupril Cap.160/2mg
Description: Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
Study NCT02250976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipilfen cap. 160mg
Description: Micronized fenofibrate 160mg
Study NCT02250976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livaro tab. 2mg
Description: Pitavastatin Ca 2mg
Study NCT03406208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 1
Description: The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
Study NCT03406208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 2
Description: The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
Study NCT02722005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: One-to-one financial coaching focused on credit, debt, savings, and income supports.
Study NCT02722005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to referral to social services
Description: Access to referral to a host of social services.
Study NCT02722005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to referral to social services
Description: Access to referral to a host of social services.
Study NCT03323138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex-PRESS and phacoemulsification